180 related articles for article (PubMed ID: 32161311)
1. Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein.
Rao H; Li X; Liu M; Liu J; Li X; Xu J; Li L; Gao WQ
Oncogene; 2020 May; 39(19):3853-3866. PubMed ID: 32161311
[TBL] [Abstract][Full Text] [Related]
2. The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2.
Essers PB; Klasson TD; Pereboom TC; Mans DA; Nicastro M; Boldt K; Giles RH; MacInnes AW
Oncogene; 2015 Feb; 34(6):771-9. PubMed ID: 24469044
[TBL] [Abstract][Full Text] [Related]
3. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
Zhou L; Yang H
PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
[TBL] [Abstract][Full Text] [Related]
4. SHARPIN regulates the development of clear cell renal cell carcinoma by promoting von Hippel-Lindau protein ubiquitination and degradation.
Yin R; Liu S
Cancer Sci; 2021 Oct; 112(10):4100-4111. PubMed ID: 34339558
[TBL] [Abstract][Full Text] [Related]
5. VHL mutation-mediated SALL4 overexpression promotes tumorigenesis and vascularization of clear cell renal cell carcinoma via Akt/GSK-3β signaling.
Sun J; Tang Q; Gao Y; Zhang W; Zhao Z; Yang F; Hu X; Zhang D; Wang Y; Zhang H; Song B; Zhang B; Wang H
J Exp Clin Cancer Res; 2020 Jun; 39(1):104. PubMed ID: 32513235
[TBL] [Abstract][Full Text] [Related]
6. Regulation of receptor for activated C kinase 1 protein by the von Hippel-Lindau tumor suppressor in IGF-I-induced renal carcinoma cell invasiveness.
He X; Wang J; Messing EM; Wu G
Oncogene; 2011 Feb; 30(5):535-47. PubMed ID: 20871634
[TBL] [Abstract][Full Text] [Related]
7. Specific von Hippel-Lindau protein expression of clear cell renal cell carcinoma with "immunogenic" features.
Magyarlaki T; Buzogány I; Nagy J
Pathol Oncol Res; 2001; 7(1):42-5. PubMed ID: 11349220
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma.
Ma X; Shen D; Li H; Zhang Y; Lv X; Huang Q; Gao Y; Li X; Gu L; Xiu S; Bao X; Duan J; Zhang X
Urol Oncol; 2015 Apr; 33(4):169.e1-11. PubMed ID: 25700976
[TBL] [Abstract][Full Text] [Related]
9. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
10. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
11. USP13 promotes deubiquitination of ZHX2 and tumorigenesis in kidney cancer.
Xie H; Zhou J; Liu X; Xu Y; Hepperla AJ; Simon JM; Wang T; Yao H; Liao C; Baldwin AS; Gong K; Zhang Q
Proc Natl Acad Sci U S A; 2022 Sep; 119(36):e2119854119. PubMed ID: 36037364
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
Liu W; Xin H; Eckert DT; Brown JA; Gnarra JR
Oncogene; 2011 Jan; 30(1):21-31. PubMed ID: 20802534
[TBL] [Abstract][Full Text] [Related]
13. von Hippel-Lindau tumor suppressor protein stimulation by thrombin involves RhoA activation.
Turcotte S; Desrosiers RR; Brand G; Béliveau R
Int J Cancer; 2004 Dec; 112(5):777-86. PubMed ID: 15386385
[TBL] [Abstract][Full Text] [Related]
14. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
Casagrande S; Ruf M; Rechsteiner M; Morra L; Brun-Schmid S; von Teichman A; Krek W; Schraml P; Moch H
J Pathol; 2013 Mar; 229(4):525-34. PubMed ID: 23007793
[TBL] [Abstract][Full Text] [Related]
15. PBRM1 and BAP1 as novel targets for renal cell carcinoma.
Brugarolas J
Cancer J; 2013; 19(4):324-32. PubMed ID: 23867514
[TBL] [Abstract][Full Text] [Related]
16. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
Moch H
Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
[TBL] [Abstract][Full Text] [Related]
17. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
Green YS; Sargis T; Reichert EC; Rudasi E; Fuja D; Jonasch E; Koh MY
Mol Cancer Res; 2019 May; 17(5):1220-1232. PubMed ID: 30705246
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma.
Turcotte S; Desrosiers RR; Beliveau R
Am J Physiol Renal Physiol; 2004 Feb; 286(2):F338-48. PubMed ID: 14583436
[TBL] [Abstract][Full Text] [Related]
20. Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma.
Guo K; Wei Y; Wang Z; Zhang X; Zhang X; Liu X; Wu W; Wu Z; Zhang L; Cui CP
Cell Death Dis; 2022 Feb; 13(2):97. PubMed ID: 35110537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]